Source comparison
Biohackers Researching Epithalon — Comparison Table
10-day IM/SC (1mg/day, 10mg total) Twice yearly with 4–6 month washout Aligns with published Khavinson trials; documented telomerase activation in lymphocytes Requires precise reconstitution and daily injections; logistically straightforward for experienced pe
This comparison does not assign a generated winner or score.
- 10-day IM/SC (1mg/day, 10mg total)
- Twice yearly with 4–6 month washout
- Aligns with published Khavinson trials; documented telomerase activation in lymphocytes
- Requires precise reconstitution and daily injections; logistically straightforward for experienced peptide users
- This is the gold-standard protocol. If replicating published outcomes is the goal, deviate at your own risk
- 20-day SC (500mcg/day, 10mg total)
- No direct trial data; extends the activation window but halves daily dose
- Easier to dose accurately; reduces injection frequency concerns; unproven efficacy
- Theoretically plausible if pulsed activation is the mechanism, but you're running an n=1 experiment
- Continuous microdose (200–500mcg daily)
- No defined cycle end; sustained administration
- Zero supporting evidence; contradicts the intermittent activation hypothesis
- Simplifies routine; highest peptide consumption per year; degrades reconstituted vials faster
- We mean this sincerely: chronic telomerase activation without washout periods is the opposite of what the evidence supports
- Oral or sublingual administration
- Variable. Typically daily
- No bioavailability data; peptides are cleaved by gastric enzymes unless chemically modified
- Convenient; avoids injections; almost certainly ineffective
- Epithalon is a tetrapeptide without enzymatic protection. It will not survive first-pass metabolism intact